Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) COO Kristen Oelschlager sold 4,153 shares of Castle Biosciences stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $35.95, for a total value of $149,300.35. Following the transaction, the chief operating officer owned 13,356 shares of the company’s stock, valued at $480,148.20. The trade was a 23.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Castle Biosciences Stock Up 3.1%
Shares of NASDAQ:CSTL traded up $1.09 during trading on Monday, reaching $36.65. 377,209 shares of the stock traded hands, compared to its average volume of 397,430. The stock has a 50-day moving average of $32.49 and a two-hundred day moving average of $26.27. Castle Biosciences, Inc. has a 52-week low of $17.72 and a 52-week high of $44.28. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04. The stock has a market cap of $1.12 billion, a P/E ratio of -55.53 and a beta of 0.94.
Castle Biosciences (NASDAQ:CSTL – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.34. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The firm had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. As a group, sell-side analysts expect that Castle Biosciences, Inc. will post -1.29 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Read Our Latest Report on Castle Biosciences
Institutional Trading of Castle Biosciences
Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. bought a new position in shares of Castle Biosciences in the 2nd quarter valued at about $78,513,000. Summit Partners Public Asset Management LLC increased its stake in Castle Biosciences by 164.7% during the fourth quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock worth $41,184,000 after acquiring an additional 658,725 shares during the last quarter. Jefferies Financial Group Inc. purchased a new stake in Castle Biosciences during the second quarter valued at approximately $15,440,000. Renaissance Technologies LLC raised its position in Castle Biosciences by 8.1% during the first quarter. Renaissance Technologies LLC now owns 532,800 shares of the company’s stock valued at $13,080,000 after purchasing an additional 39,700 shares during the period. Finally, AIGH Capital Management LLC purchased a new stake in Castle Biosciences during the second quarter valued at approximately $13,001,000. 92.60% of the stock is currently owned by institutional investors.
Castle Biosciences Company Profile
Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to provide personalized information for patients with cancer and other serious diseases. Its products analyze biological characteristics in tissue samples to help physicians assess disease risk, guide treatment decisions and support patient management.
The company’s portfolio includes diagnostic tests for skin cancers, such as DecisionDx-Melanoma for assessing metastatic risk in patients with cutaneous melanoma and DecisionDx-SCC for evaluating metastatic risk in certain cases of cutaneous squamous cell carcinoma.
Featured Articles
- Five stocks we like better than Castle Biosciences
- NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run
- A Manufacturing Surprise Could Be a Big Win for These 2 Companies
- What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions
- 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
